Meeting
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
Authors
Jorge E. Cortes
The University of Texas MD Anderson Cancer Center, Houston, TX
Jorge E. Cortes , Javier Pinilla-Ibarz , Philipp D. Le Coutre , Ronald Paquette , Charles Chuah , Franck E. Nicolini , Jane Apperley , Hanna Jean Khoury , Moshe Talpaz , Michele Baccarani , Stephanie Lustgarten , Frank G. Haluska , Francois Guilhot , Michael W.N. Deininger , Andreas Hochhaus , Timothy P Hughes , Neil P. Shah , Hagop M. Kantarjian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Chronic Leukemia—CML
Clinical Trial Registration Number
NCT01207440
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7013)
DOI
10.1200/JCO.2016.34.15_suppl.7013
Abstract #
7013
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
First Author: Hagop M. Kantarjian
Poster
2014 ASCO Annual Meeting
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
First Author: Hagop M. Kantarjian
First Author: Ronald J. Rieder
Poster
2014 ASCO Annual Meeting
Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
First Author: Moshe Talpaz